Post-Marketing Surveillance Related to Medication Errors

With the recent onslaught of proposed FDA guidances related to risk assessment, risk management, and pharmacovigilance, pharmaceutical companies are expanding their post-marketing surveillance systems to detect adverse drug events related to medication errors, including events related to nomenclature problems.

Using our MONIT-ERR or EVALUATE-ERR services, Med-E.R.R.S. can help, regardless of whether you have a Phase IV commitment for a specific product, or you wish to take a proactive approach for all products. Our experts in medication error identification and prevention have the tools and experience needed to monitor, classify, and analyze actual or "near-miss" adverse events to determine if they are related to medication errors. We categorize these events according to the National Coordinating Council on Medication Error Reporting and Prevention (NCC-MERP) Classification, collate them, and provide you with reports at regular intervals.